abrdn Income Credit Strategies ACP Pharma — Goodwill Gross
Other segment segments
Other financials
Where this comes from
Reported directly by abrdn Income Credit Strategies in its filing.
Tagged under the XBRL concept us-gaap:GoodwillGross.
The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about abrdn Income Credit Strategies's pharma — goodwill gross.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is abrdn Income Credit Strategies's pharma — goodwill gross?
- abrdn Income Credit Strategies (ACP) reported pharma — goodwill gross of $13M in Q1 2026.
- How has abrdn Income Credit Strategies's pharma — goodwill gross changed year-over-year?
- abrdn Income Credit Strategies's pharma — goodwill gross decreased by 0.0% year-over-year, from $13M to $13M.
- What is the long-term trend for abrdn Income Credit Strategies's pharma — goodwill gross?
- Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — goodwill gross has grown at a 0.0% compound annual growth rate (CAGR), from $52M to $52M.
- What does pharma — goodwill gross mean?
- The total acquisition cost assigned to the pharmaceutical segment that exceeds the fair value of identifiable net assets. It represents the initial premium paid for intangible assets such as brand reputation, intellectual property, and market presence before any accumulated impairment.